Acasunlimab (DuoBody-PD-L1x4-1BB)

About Genmab

Founded in 1999, Genmab's mission is to improve the lives of patients through innovative antibody therapeutics. The company has achieved remarkable success with its partnered assets, DARZALEX® and KESIMPTA®, which have become multi-billion dollar therapies, validating its scientific approach. Its strategy combines advancing a deep, wholly-owned clinical pipeline with high-value collaborations, funded by substantial royalty revenue. This hybrid model positions Genmab to sustainably capture value from both its platform innovation and direct drug development.

Therapeutic Areas

Other Non-Small Cell Lung Cancer Drugs